Royalty Pharma plc (Nasdaq: RPRX) has priced an offering of $2.0 billion of senior unsecured notes, with $600 million due in 2031, $900 million due in 2035, and $500 million due in 2055. The offering is expected to close on September 16, 2025, and the proceeds will be used for general corporate purposes. BofA Securities, Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley, and TD Securities are acting as book-running managers. The Notes are offered under an effective shelf registration statement filed with the SEC. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation in the industry.

For more information, contact Royalty Pharma Investor Relations at +1 (212) 883-6772 or [email protected].

Read more at GlobeNewswire: Royalty Pharma Announces Pricing of $2.0 Billion of Senior